Angiogenic action of compound GK-2, a dimeric dipeptide mimetic of loop 4 of nerve growth factor (NGF), was studied in in vitro and in vivo experiments. Experiments on human endothelial cell culture HUVEC showed that compound GK-2 significantly (p<0.05) stimulated the initial stage of angiogenesis, and its angiogenic activity was not inferior to the reference neurotrophin NGF. In experiments with hindlimb ischemia modeled in rats, GK-2 (1 mg/kg intraperitoneally for 14 days) significantly increased the total length of capillary vessels (p<0.003) and the number of vessels per 1 mm2 ischemic tissue (p<0.001) in comparison with the control. Our findings indicate that under experimental conditions compound GK-2 exhibits not only angiogenic, but also anti-ischemic activity.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Gudasheva TA, Antipova TA, Konstantinopolsky MA, Povarnina PY, Seredenin SB. Nerve growth factor novel dipeptide mimetic GK-2 selectively activates TrkA postreceptor signaling pathways and does not cause adverse effects of native neurotrophin. Doklady Biochemistry and Biophysics. 2014:456(1):88-91.
Gudasheva TA, Antipova TA, Seredenin SB. Novel low-molecular-weight mimetics of the nerve growth factor. Doklady Biochemistry and Biophysics. 2010:434(1):262-265.
Kryzhanovskii SA, Vititnova MB. Cardiovascular effects of nerve growth factor: An analytical review. Part II. Human Physiology. 2011:37(3):361-378.
Parfenova EV, Tkachuk VA. Therapeutic angiogenesis: achievements, problemsm prospects. Kardiol. Vestn. 2007:II(2):5-14. Russian.
Blais M, Lévesque P, Bellenfant S, Berthod F. Nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3 and glial-derived neurotrophic factor enhance angiogenesis in a tissue-engineered in vitro model. Tissue Eng. Part A. 2013:19(15-16):1655-1664.
Freedman SB, Isner JM. Therapeutic angiogenesis for coronary artery disease. Ann. Intern. Med. 2002:136(1):54-71.
Gudasheva TA, Povarnina PYu, Antipova TA, Seredenin SB. A Novel dimeric dipeptide mimetic of the nerve growth factor exhibits pharmacological effects upon systemic administration and has no side effects accompanying the neurotrophin treatment. Neurosci. Med. 2014:5:101-108. doi: 10.4236/nm.2014.52013.
Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER.; VIVA Investigators. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation. 2003:107(10):1359-1365.
Kim YS, Jo DH, Lee H, Kim JH, Kim KW, Kim JH. Nerve growth factor-mediated vascular endothelial growth factor expression of astrocyte in retinal vascular development. Biochem. Biophys. Res. Commun. 2013:431(4):740-745.
Ko SH, Bandyk DF. Therapeutic angiogenesis for critical limb ischemia. Semin. Vasc. Surg. 2014:27(1):23-31.
Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ, Annex BH.; TRAFFIC Investigators. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet. 2002:359):2053-2058.
Lei Y, Haider HKh, Shujia J, Sim ES. Therapeutic angiogenesis. Devising new strategies based on past experiences. Basic Res. Cardiol. 2004:99(2):121-132.
Mitsos S, Katsanos K, Koletsis E, Kagadis GC, Anastasiou N, Diamantopoulos A, Karnabatidis D, Dougenis D. Therapeutic angiogenesis for myocardial ischemia revisited: basic biological concepts and focus on latest clinical trials. Angiogenesis. 2012:15(1):1-22.
Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Süselbeck T, Werner N, Haase J, Neuzner J, Germing A, Mark B, Assmus B, Tonn T, Dimmeler S, Zeiher AM.; REPAIR-AMI Investigators. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur. Heart J. 2006:27(23):2775-2783.
Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, Gervino EV, Pike M, Whitehouse MJ, Moon T, Chronos NA. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation. 2002:105(7):788-793.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 161, No. 4, pp. 503-507, April, 2016
Rights and permissions
About this article
Cite this article
Kryzhanovskii, S.A., Antipova, T.A., Tsorin, I.B. et al. Angiogenic Effects of Dimeric Dipeptide Mimetic of Loop 4 of Nerve Growth Factor. Bull Exp Biol Med 161, 513–517 (2016). https://doi.org/10.1007/s10517-016-3450-y
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-016-3450-y